Volastra Therapeutics is developing drugs that target a vulnerability of cancer cells - chromosomal instability, or CIN. CIN is present in 60-80% of cancers and is associated with poor survival in many patients.  By using their proprietary CINtech platform that incorporates cancer biology, data sciences and medicinal chemistry, Volastra is turning a deep biological understanding of CIN into life-saving therapies. The tools Volastra is using range from CIN CRISPR screen, CIN imaging and genomics to molecular structure-activity analysis. Volastra is initially focusing on two therapeutic approaches: synthetic lethality and immune activation, with programs in early development.

<p>Volastra Therapeutics is developing drugs that target a vulnerability of cancer cells - chromosomal instability, or CIN. CIN is present in 60-80% of cancers and is associated with poor survival in many patients.  By using their proprietary CINtech platform that incorporates cancer biology, data sciences and medicinal chemistry, Volastra is turning a deep biological understanding of CIN into life-saving therapies. The tools Volastra is using range from CIN CRISPR screen, CIN imaging and genomics to molecular structure-activity analysis. Volastra is initially focusing on two therapeutic approaches: synthetic lethality and immune activation, with programs in early development.</p>


Volastra Therapeutics

1361 Amsterdam Ave
Suite 520
New York, NY 10027


							Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline
							Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly.  Funding will support clinical development of Volastra’s […]
							
								
									March 7, 2023
								
								
									
								
							
						

 Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics 

Companies To Watch: Volastra Therapeutics - Life Science Leader Magazine

Abstract 517: Targeting chromosomally unstable tumors with a selective KIF18A inhibitor


							Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference
							Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on […]
							
								
									September 9, 2022
								
								
									
								
							
						

 Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib 

Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics - CRISPR Medicine News

 Volastra Therapeutics Expands Leadership Team to Tackle Cancer 


							Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021
							Dr. Bakhoum will present on the critical role of chromosomal instability in cancer metastasis. NEW YORK, April 8, 2021 – […]
							
								
									April 8, 2021
								
								
									
								
							
						


						Volastra Therapeutics Forms New Partnerships to Advance KIF18A Inhibitors in Cancer
						
							
								March 27, 2024
								The Clinical Trial Vanguard
							
							
								
							
						
					

 Volastra Therapeutics on LinkedIn: #hiring #oncology #researchassociate #biotechjobs #volastratherapeutics… 

Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023


						Volastra vies for the next big synthetic lethality target
						
							
								April 19, 2024
								ApexOnco
							
							
								
							
						
					


							Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022
							NEW YORK, September 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today […]
							
								
									September 12, 2022
								
								
									
								
							
						


						Companies To Watch: Volastra Therapeutics
						
							
								June 26, 2024
								Life Science Leader
							
							
								
							
						
					

Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors

 Bristol Myers Squibb Embarks Oncology Pact With Volastra Therapeutics 

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer


						Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’
						
							
								March 21, 2022
								Fierce Biotech
							
							
								
							
						
					


							Volastra Therapeutics Announces Participation in 2022 Guggenheim Synthetic Lethality Day
							NEW YORK, May 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN) as a vulnerability […]
							
								
									May 12, 2022
								
								
									
								
							
						

Non-cell-autonomous cancer progression from chromosomal instability

Last week, we gathered at Volastra for a Thanksgiving celebration. It was a joy to come together, share a meal, and reflect on the amazing work we’re doing to make a difference for patients.

We’re thankful for our dedicated team and the impact we’re building together. From all of us at Volastra, Happy Thanksgiving to you and your loved ones! 🦃🍂 #Volastra #Thanksgiving2024


              New Frontiers in Targeting Chromosomal Instability
            

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022 - Business Wire

Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb - Business Wire


						Volastra Therapeutics has now raised $44M, partners with Microsoft
						
							
								April 6, 2021
								New York Business Journal
							
							
								
							
						
					


							Volastra Therapeutics and Dewpoint Therapeutics Partner to Discover Novel Condensate Modulators for Cancer Treatment
							NEW YORK and BOSTON, March 9, 2021 /PRNewswire/ — Volastra Therapeutics and Dewpoint Therapeutics today announced a research and development partnership to discover novel modulators of biomolecular condensates […]
							
								
									March 9, 2021
								
								
									
								
							
						


						Volastra Therapeutics Names First CEO
						
							
								September 16, 2020
								Wall Street Journal
							
							
								
							
						
					

 Volastra Therapeutics on LinkedIn: #kif18a #cancers #asco24 


						Volastra licenses Amgen molecule for chromosomally unstable cancers
						
							
								March 7, 2023
								C&EN
							
							
								
							
						
					


							Volastra Therapeutics Launches with $12 Million in Seed Financing to Develop Novel Metastatic Cancer Therapies
							Polaris Partners led financing round for New York City-based start-up Company to focus on the treatment of metastatic cancers through […]
							
								
									February 11, 2020
								
								
									
								
							
						

Volastra taps CSO as it looks to expand research horizons - Fierce Biotech

Press Release Service: Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer - CRISPR Medicine News

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline - Business Wire

Discovery of potent, orally active KIF18A inhibitors targeting CIN-high cancer cells.

Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib - Business Wire

 Systems and methods for evaluation of chromosomal instability using machine- … 


							Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis
							Company founded by Polaris Partners with latest financing led by Vida Ventures  Funding will support advancement of novel approaches to […]
							
								
									April 6, 2021
								
								
									
								
							
						


						Volastra bumps up seed round to $44M, inks Microsoft partnership to tackle cancer metastasis
						
							
								April 6, 2021
								Fierce Biotech
							
							
								
							
						
					


						Volastra’s Strong Year Continues with Microsoft Deal and Extended Seed Financing
						
							
								April 6, 2021
								BioSpace
							
							
								
							
						
					

We’re Hiring: Director, Development Program Management, Oncology!

Volastra Therapeutics is looking for a driven leader to join our team as Director of Development Program Management, Oncology. Reporting to the Chief Medical Officer, this role is important in managing our oncology development programs, ensuring smooth integration across functions, and driving key milestones.

If you have experience working on clinical-stage oncology programs and want to make an impact in a fast-paced biotech environment, we’d love to hear from you: https://lnkd.in/eE7h-mCX

#BiotechCareers #Oncology #ProgramManagement #PharmaJobs #VolastraTherapeutics #NowHiring #NYCJobs

We were thrilled to participate in the 2nd Annual Life Sciences Day last week, hosted by Life Science Cares New York.

Volastra had the pleasure of hosting more than 50 high school students at our state-of-the art Harlem-based lab, giving them a behind-the-scenes look at how cancer therapies are developed and the various career opportunities that exist at biotechnology companies.

Our team shared insights into the science, dedication, and collaboration that fuel our development of novel cancer therapies. 

A huge thank you to Life Science Cares and everyone who made this day possible – we look forward to continued partnership and many more impactful events ahead.

#LifeSciences #Biotech #FutureLeaders #Oncology

Volastra licenses Amgen molecule for chromosomally unstable cancers - Chemical & Engineering News

 Spiro indoline inhibitors of kif18a 

Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors

Volastra Therapeutics initiates dosing in Phase Ib ovarian cancer trial - Clinical Trials Arena

Volastra Therapeutics presents new KIF18A inhibitors for cancer - BioWorld Online


						Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor
						
							
								March 7, 2023
								BioSpace
							
							
								
							
						
					

Volastra Therapeutics Appoints Samuel Bakhoum, M.D., Ph.D., as Chief Scientific Officer - citybiz

Notables in Health Care 2021: Charles Hugh-Jones, M.D. - Crain's New York Business


						Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A
						
							
								March 7, 2023
								Endpoints News
							
							
								
							
						
					


							Volastra Therapeutics Partners with Microsoft to Advance Metastatic Cancer Research
							Collaboration will integrate Microsoft Azure AI and Volastra’s insights into tumor biology to develop machine learning tools to detect drivers […]
							
								
									April 6, 2021
								
								
									
								
							
						

Akanksha Verma - STAT

Women of Influence honoree: Diane Tager, Volastra Therapeutics - The Business Journals

Join Our Team!

Volastra Therapeutics is seeking a detail-oriented Clinical Trial Associate. This role will support our oncology clinical trials, driving excellence in execution and helping us bring new treatments to patients.
If you’re passionate about advancing clinical research in a collaborative, fast-paced environment, check out the full role description and apply here: https://lnkd.in/enN9bExa

#Hiring #ClinicalTrials #OncologyResearch #LifeSciences #BiotechCareers #Oncology #VolastraTherapeutics #NowHiring #NYCJobs

 Compounds for inhibiting kif18a 


							Volastra Therapeutics Appoints Charles Hugh-Jones as Chief Executive Officer
							NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, a biotechnology company developing novel therapies to treat and prevent the formation of metastatic disease, has […]
							
								
									September 16, 2020
								
								
									
								
							
						

Targeting the undruggable - Science


						Armed with $60M series A and Lilly’s backing, Volastra enters clinic via Amgen cancer med
						
							
								March 7, 2023
								Fierce Biotech
							
							
								
							
						
					

Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor - BioSpace

Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023 - Business Wire

Volastra Therapeutics Appoints Charles Hugh-Jones as Chief Executive Officer - Business Wire

Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med - Fierce Biotech

BMS’s Big March Continues with $1B Volastra Oncology Alliance - BioSpace

We’re excited to announce the US Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, our internally discovered #KIF18A inhibitor for the treatment of #patients with platinum-resistant high-grade serous #ovariancancer (HGSOC).

This designation further underscores the potential of KIF18A inhibition to address the high unmet need in treating HGSOC and takes us one step closer to delivering new treatment options to patients. Read more about the news: https://lnkd.in/gBNtYTPW

Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib


              Translating Science for Maximum Patient Impact
            

 INDOLINE KIF18A INHIBITORS 

Volastra Therapeutics Keeps Mink Building Lab Space - Commercial Observer

 Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of ... 

 Ex-Allergan CMO takes the helm at Lewis Cantley's metastasis-focused biotech startup 


							Volastra Therapeutics Expands Leadership Team to Tackle Cancer
							Company brings in experienced biopharma leaders to head translational, data science and business development functions and expands scientific leadership team […]
							
								
									November 16, 2021
								
								
									
								
							
						

Volastra Therapeutics Granted FDA Fast Track Designation for Novel KIF18A Inhibitor in  Ovarian Cancer

Volastra Therapeutics Granted FDA Fast Track Designation for Novel KIF18A Inhibitor in Ovarian Cancer - Business Wire

American Association for Cancer Research

We're Hiring a Senior Vice President of Legal, Compliance, and Operations!

Volastra Therapeutics is seeking a strategic leader with deep expertise in the biotechnology industry to join our team. As the SVP of Legal, Compliance, and Operations, you will oversee our legal affairs, corporate compliance, and operational functions to drive efficiency and ensure we meet the highest regulatory and ethical standards.

Are you ready to lead in a dynamic, fast-growing environment? Join us on our mission to innovate in oncology.

👉 Apply here: https://lnkd.in/eKfkMZQV

#NowHiring #BiotechCareers #LegalJobs #Biotechnology #Oncology #VolastraTherapeutics #NYCJobs 

Volastra Therapeutics Announces the Appointment of Co-Founder Samuel Bakhoum, M.D., Ph.D., as Chief Scientific Officer - Business Wire

FDA grants fast track status for Volastra’s VLS-1488 to treat ovarian cancer - Pharmaceutical Business Review

We’re thrilled to welcome our co-founder, Samuel Bakhoum, M.D., Ph.D., to the Volastra team as Chief Scientific Officer! Dr. Bakhoum is a renowned physician-scientist and leader in #cancer research, who has pioneered work in the field of #chromosomal_instability (CIN).
 
Learn more about Dr. Bakhoum and read the full press release here: https://lnkd.in/eiKfcjA4

Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics - Business Wire

 Volastra Therapeutics presents new KIF18A inhibitors for cancer 

Amgen deal, $60M round allow Volastra to advance pair of KIF18A products - BioCentury

 Tricyclic sulfoximine inhibitors of enpp1 

Dewpoint, with a handful of Big Pharma partners from Merck to Pfizer, collects $150M to advance its 20 programs - Fierce Biotech

 Volastra Therapeutics Adds $12M in Funding to Stop Metastasis of Cancer 


							Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
							Bristol Myers Squibb to leverage Volastra’s proprietary CINtech platform to discover and develop oncology drug candidates Volastra to receive an […]
							
								
									March 21, 2022
								
								
									
								
							
						

 Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors 

www.volastratx.com

Volastra Therapeutics is seeking a talented Clinical Research Associate (CRA) to join our team. This role will support key clinical trial operations, from start-up to close-out, driving progress in our mission to revolutionize oncology research.
If you’re detail-oriented, collaborative, and eager to thrive in a fast-paced biotech environment, this could be the perfect opportunity to grow your career.

https://lnkd.in/eHBSvA_i
 
#Hiring #ClinicalResearch #ClinicalTrials #LifeSciences #BiotechCareers #Oncology #VolastraTherapeutics #NowHiring #NYCJobs


Volastra Therapeutics Announces the Appointment of Co-Founder Samuel Bakhoum, M.D., Ph.D., as Chief Scientific Officer

 Women of Influence honoree: Diane Tager, Volastra Therapeutics 

 Volastra Therapeutics Names First CEO 

 Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to ... 

Volastra Therapeutics

Business:

Drug notes:

About: